nach oben

Heart Failure Reviews

Erschienen in:

22.03.2016

The role of pharmacotherapy in the prevention of sudden cardiac death in patients with heart failure

verfasst von: Phillip A. Weeks, Adam Sieg, Jennifer Ann Gass, Indranee Rajapreyar

Erschienen in: Heart Failure Reviews | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Sudden cardiac death remains a significant threat to the survival of patients with heart failure. Long-term cardiac remodeling predisposes these patients to develop malignant ventricular arrhythmias. Permanent implantable and temporary external defibrillators remain a mainstay for the prevention of sudden cardiac death in this population. For decades, researchers have attempted to identify reliable drug therapies to avoid such arrhythmias; however, to date, success has been inconsistent. This review aims to explore the evidence defining the role of drug therapies for direct and indirect suppression of arrhythmias that may cause sudden cardiac death in patients with heart failure.

The CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 316:1429–1435CrossRef

Pitt B, Zannad F, Remme WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341:709–717CrossRefPubMed

Chugh SS, Reinier K, Teodorescu C et al (2008) Epidemiology of sudden cardiac death: clinical and research implications. Prog Cardiovasc Dis 51:213–228CrossRefPubMedPubMedCentral

Stecker EC, Vickers C, Waltz J et al (2006) Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the Oregon Sudden Unexpected Death Study. J Am Coll Cardiol 47:1161–1166CrossRefPubMed

Rea TD, Pearce RM, Raghunathan TE et al (2004) Incidence of out-of-hospital cardiac arrest. Am J Cardiol 93:1455–1460CrossRefPubMed

Deo R, Albert CM (2012) Epidemiology and genetics of sudden cardiac death. Circulation 125:620–637CrossRefPubMedPubMedCentral

Mozaffarian D, Benjamin EJ, Go AS et al (2015) Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation 131:e29–e322CrossRefPubMed

Huikuri HV, Castellanos A, Myerburg RJ (2001) Sudden death due to cardiac arrhythmia. N Engl J Med 345:1473–1482CrossRefPubMed

Bayes de Luna A, Coumel P, Leclereq JF (1989) Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J 117:151–159CrossRefPubMed

10.

Yancy CW, Jessup M, Bozkurt B et al (2013) 2013 American College of Cardiology Foundation/American Heart Association guidelines for the management of heart failure. J Am Coll Cardiol 62:1495–1539CrossRef

11.

Priori SG, Blomstrom-Lundqvist C, Mazzanti A et al (2015) 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 36:2793–2867CrossRefPubMed

12.

Zipes DP, Camm AJ et al (2006) ACC/AHA/ESC 2006 guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. J Am Coll Cardiol 48:e247–e346CrossRefPubMed

13.

Reiter MJ, Stromberg KD, Whitman TA et al (2013) Influence of intra-cardiac pressure on spontaneous ventricular arrhythmias in patients with systolic heart failure: insights from the REDUCEhf Trial. Circ Arrhythm Electrophysiol 6:272–278CrossRefPubMed

14.

Fukuda K, Kanazawa H, Aizawa Y et al (2015) Cardiac innervation and sudden cardiac death. Circ Res 116:2005–2019CrossRefPubMedPubMedCentral

15.

Cao JM, Chen LS, KenKnight BH et al (2000) Nerve sprouting and sudden cardiac death. Circ Res 86:816–821CrossRefPubMed

16.

Fischer TH, Eiringhaus J, Dybkova N et al (2014) Ca²⁺/calmodulin-dependent protein kinase II equally induces sarcoplasmic reticulum Ca²⁺ leak in human ischaemic and dilated cardiomyopathy. Eur J Heart Fail 16:1292–1300CrossRefPubMed

17.

Kirchhefer U, Schmitz W, Scholz H et al (1999) Activity of cAMP-dependent protein kinase and Ca²⁺/calmodulin-dependent protein kinase in failing and non-failing human hearts. Cardiovasc Res 42:254–261CrossRefPubMed

18.

Ai X, Curran JW, Shannon TR et al (2005) Ca²⁺/calmodulin-dependent protein kinase modulates cardiac ryanodine receptor phosphorylation and sarcoplasmic reticulum Ca²⁺ leak in heart failure. Circ Res 97:1314–1322CrossRefPubMed

19.

Van Oort RJ, McCauley MD, Dixit SS et al (2010) Ryanodine receptor phosphorylation by calcium/calmodulin-dependent protein kinase II promotes life-threatening ventricular arrhythmias in mice with heart failure. Circulation 122:2669–2679CrossRefPubMedPubMedCentral

20.

Bardy GH, Lee KL, Mark DB et al (2005) Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352:225–237CrossRefPubMed

21.

Herre JM, Sauve MJ, Malone P et al (1989) Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. J Am Coll Cardiol 13:442–449CrossRefPubMed

22.

Connolly SJ, Hallstrom AP, Cappato R et al (2000) Meta-analysis of implantable cardioverter-defibrillator secondary prevention trials. Eur Heart J 21:2071–2078CrossRefPubMed

23.

Reddy VY, Reynolds MR, Neuzil P et al (2007) Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med 357:2657–2665CrossRefPubMedPubMedCentral

24.

Kuck KH, Schaumann A, Eckardt L et al (2010) Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicenter randomized controlled trial. Lancet 375:31–40CrossRefPubMed

25.

Ruskin JN (1989) The cardiac arrhythmia suppression trial (CAST). N Engl J Med 321:386–388CrossRefPubMed

26.

Echt DS, Liebson PR, Mitchell LB et al (1991) Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med 324:781–788CrossRefPubMed

27.

Verlinden NJ, Coons JC (2015) Disopyramide for hypertrophic cardiomyopathy: a pragmatic reappraisal of an old drug. Pharmacotherapy 35:1164–1172CrossRefPubMed

28.

U.K. Rythmodan Multicentre Study Group (1984) Oral disopyramide after admission to hospital with suspected acute myocardial infarction. Postgrad Med J 60:98–107CrossRef

29.

Belhassen B, Glick A, Viskin S et al (2004) Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation 110:1731–1737CrossRefPubMed

30.

Alings M, Dekker L, Sadee A et al (2001) Quinidine induced electrocardiographic normalization in two patients with Brugada syndrome. Pacing Clin Electrophysiol 24:1420–1422CrossRefPubMed

31.

Sharma AD, Purves P, Yee R et al (1990) Hemodynamic effects of intravenous procainamide during ventricular tachycardia. Am Heart J 119:1034–1041CrossRefPubMed

32.

Hine LK, Laird N, Hewitt P et al (1989) Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction. Arch Intern Med 149:2694–2698CrossRefPubMed

33.

MacMahon S, Collins R, Peto R et al (1988) Effects of prophylactic lidocaine in suspected acute myocardial infarction: an overview of results from the randomized, controlled trials. JAMA 260:1910–1916CrossRefPubMed

34.

Singh S, Klein R, Eisenberg B et al (1990) Long-term effect of mexiletine on left ventricular function and relation to suppression of ventricular arrhythmia. Am J Cardiol 66:1222–1227CrossRefPubMed

35.

Chamberlain DA, Jewitt DE, Julian DG et al (1980) Oral mexiletine in high-risk patients after myocardial infarction. Lancet 2:1324–1327CrossRefPubMed

36.

Stein J, Podrid P, Lown B (1984) Effects of oral mexiletine on left and right ventricular function. Am J Cardiol 54:575–578CrossRefPubMed

37.

Cardiac Arrhythmia Suppression Trial II Investigators (1992) Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 327:227–233CrossRef

38.

Kuck KH, Cappato R, Siebels J et al (2000) Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 102:748–754CrossRefPubMed

39.

Burkart F, Pfisterer M, Kiowski W et al (1990) Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol 16:1711–1718CrossRefPubMed

40.

Doval HC, Nul DR, Grancelli HO et al (1994) Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrvida en la insuficiencia cardiac en Argentina. Lancet 344:493–498CrossRefPubMed

41.

Singh SN, Fletcher RD, Gross Fisher S et al (1995) Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 333:77–82CrossRefPubMed

42.

Julian DG, Camm AJ, Frangin G et al (1997) Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 349:667–674CrossRefPubMed

43.

Cairns JA, Connolly SJ, Roberts R et al (1997) Randomised trial of outcomes after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 349:675–682CrossRefPubMed

44.

Connolly S, Cairns J, Gent M, (Amiodarone Trials Meta-Analysis Investigators) et al (1997) Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomized trials. Lancet 350:1417–1424CrossRef

45.

Piccini JP, Berger JS, O’Connor CM (2009) Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized trials. Eur Heart J 30:1245–1253CrossRefPubMed

46.

Kober L, Torp-Pederson C, McMurray JJV et al (2008) Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 358:2678–2687CrossRefPubMed

47.

Waldo AL, Camm AJ, deRuyter H et al (1996) Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 348:7–12CrossRefPubMed

48.

Kuhlkamp V, Mewis C, Mermi J et al (1999) Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment. J Am Coll Cardiol 33:46–52CrossRefPubMed

49.

Pacifico A, Hohnloser SH, Williams JH et al (1999) Prevention of implantable-defibrillator shocks by treatment with sotalol. N Engl J Med 340:1855–1862CrossRefPubMed

50.

Torp-Pedersen C, Moller M, Thomsen PEB, (DIAMOND Study Group) et al (1999) Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med 341:857–865CrossRefPubMed

51.

Kober L, Thomsen PEB, Moller M, (DIAMOND Study Group) et al (2000) Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomized trial. Lancet 356:2052–2058CrossRefPubMed

52.

Mann DL, Bristow MR (2005) Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 11:2837–2849CrossRef

53.

McMurray J (2010) Systolic heart failure. N Engl J Med 362:228–238CrossRefPubMed

54.

Chekakie MO (2012) Traditional heart failure medications and sudden cardiac death prevention: a review. J Cardiovasc Pharmacol Ther 18:412–426CrossRef

55.

Packer M, Bristow MR, Cohn JN et al (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334:1349–1355CrossRefPubMed

56.

CIBIS-II Investigators and Committees (1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomised trial. Lancet 353:9–13 CrossRef

57.

Hjalmarson A, Goldstein S, Fagerberg B et al (2000) Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure. JAMA 283:1285–1302CrossRef

58.

Bristow MR, Gilbert EM, Abraham WT et al (1996) Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 94:2807–2816CrossRefPubMed

59.

Packer M, Coats AJS, Fowler MB et al (2001) Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651–1658CrossRefPubMed

60.

Packer M, Fowler MB, Roecker EB et al (2002) Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the COPERNICUS Study. Circulation 106:2194–2199CrossRefPubMed

61.

CIBIS Investigators and Committees (1994) A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994(90):1765–1773

62.

Poole-Wilson P, Swedberg K, Cleland J et al (2003) Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362:7–13CrossRefPubMed

63.

The Beta-Blocker Evaluation of Survival Trial Investigators (2001) A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 344:1659–1667CrossRef

64.

CAPRICORN Investigators (2001) Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 357:1385–1390CrossRef

65.

Al-Gobari M, Khatib CE, Pillon F et al (2013) Beta-blockers for the prevention of sudden cardiac death in heart failure patients: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord 13:52–60CrossRefPubMedPubMedCentral

66.

Domanski MJ, Exner DV, Borkowf CB et al (1999) Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infraction. J Am Coll Cardiol 33:598–604CrossRefPubMed

67.

Cleland JG, Erhardt L, Murray G et al (1993) Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 342:821–828

68.

Cleland JG, Erhardt L, Murray G et al (1997) Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators. Eur Heart J 18:41–51CrossRefPubMed

69.

Kober L, Torp-Pedersen C, Carlsen JE et al (1995) A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 333:1670–1676CrossRefPubMed

70.

Naccarella F, Naccarelli GV, Maranga SS et al (2002) Do ACE inhibitors or angiotensin II antagonists reduce total mortality and arrhythmic mortality? A critical review of controlled clinical trials. Curr Opin Cardiol 17:6–18CrossRefPubMed

71.

Cohn JN, Johnson G, Ziesche S et al (1991) A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325:303–310CrossRefPubMed

72.

Pitt B, Segal R, Martinez FA et al (1997) Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349:747–752CrossRefPubMed

73.

Pitt B, Poole-Wilson PA, Segal R et al (2000) Effect of losartan compared with captopril in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet 355:1582–1587CrossRefPubMed

74.

Dickstein K, Kjekshus J, the OPTIMAAL Steering Committee (2002) Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 360:752–760CrossRefPubMed

75.

Granger CB, McMurray J, Yusuf S et al (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362:772–776CrossRefPubMed

76.

McMurray J, Ostergren J, Swedberg K et al (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362:767–771CrossRefPubMed

77.

Solomon SD, Wang D, Finn P et al (2004) Effect of candesartan on cause-specific mortality in heart failure patients. Circulation 110:2180–2183CrossRefPubMed

78.

Konstam MA, Neaton JD, Dickstein K et al (2009) Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 374:1840–1848CrossRefPubMed

79.

Zannad F, Dousset B, Alla F (2001) Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship. Hypertension 38(5):1227–1232CrossRefPubMed

80.

Pitt B, Remme W, Zannad F et al (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309–1321CrossRefPubMed

81.

Zannad F, McMurray J, Krum H et al (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364:11–21CrossRefPubMed

82.

Filippatos G, Anker SD, Bohm M, et al (2015) Results of the ARTS-HF: finerenone versus eplerenone in patients with worsening chronic heart failure and diabetes and/or chronic kidney disease. http://www.escardio.org/static_file/Escardio/Press-media/Press%20releases/2015/Congress/ARTS-HF_Filippatos.pdf. 4 Nov 2015

83.

Pedersen TR, Kjekshus J, Berg K et al (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Survival Study (4s). Lancet 344(8934):1383–1389

84.

LaRosa J, Grundy S, Waters D et al (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352(14):1425–1435CrossRefPubMed

85.

Nissen S, Nicholls S, Sipahi I et al (2006) Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. JAMA 295:1556–1565CrossRefPubMed

86.

Shanes J, Minadeo K, Moret A et al (2007) Statin therapy in heart failure: prognostic effects and potential mechanisms. Am Heart J 154:617–623CrossRefPubMed

87.

Bonetti P, Lerman L, Napoli C et al (2003) Statin effects beyond lipid lowering—are they clinically relevant? Eur Heart J 24:225–248CrossRefPubMed

88.

Fonarow G, Wright R, Spencer F et al (2005) Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol 96:611–616CrossRefPubMed

89.

Mitchell L, Powell J, Gillis A et al (2003) Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the antiarrhythmics versus implantable defibrillators (AVID) trial. J Am Coll Cardiol 42:81–87CrossRefPubMed

90.

Vyas A, Guo H, Moss A et al (2006) Reduction in ventricular tachyarrhythmias with statins in the multicenter automatic defibrillator implantation trial (MADIT)-II. J Am Coll Cardiol 47:769–773CrossRefPubMed

91.

Liao Y, Hsieh Y, Hung C et al (2013) Statin therapy reduces the risk of ventricular arrhythmias, sudden cardiac death, and mortality in heart failure patients: a nationwide population-based cohort study. Int J Cardiol 168(5):4805–4807CrossRefPubMed

92.

Vrtovec B, Okrajsek R, Golicnik A et al (2008) Atorvastatin therapy may reduce the incidence of sudden cardiac death in patients with advanced chronic heart failure. J Card Fail 14:140–144CrossRefPubMed

93.

Goldberger J, Subacius H, Schaechter A et al (2006) Effects of statin therapy on arrhythmic events and survival in patients with non-ischemic dilated cardiomyopathy. J Am Coll Cardiol 48:1228–1233CrossRefPubMed

94.

Kjekshus J, Apetrei E, Barrios V et al (2007) Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357(22):2248–2261CrossRefPubMed

95.

Tavazzi L, Maggioni AP, Marchioli R et al (2008) Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet 372:1231–1239CrossRefPubMed

96.

Wang J, Wu G, Wang Z et al (2014) Long-term clinical outcomes of statin use for chronic heart failure: a meta-analysis of 15 prospective studies. Heart Lung Circ 23:105–113CrossRefPubMed

97.

Gheorghiage M, Bohm M, Greene S et al (2013) Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure. JAMA 309(11):1125–1135CrossRef

98.

Tavazzi L, Maggioni A, Marchioli R et al (2008) Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet 372:1223–1230CrossRefPubMed

Titel: The role of pharmacotherapy in the prevention of sudden cardiac death in patients with heart failure
verfasst von: Phillip A. Weeks
Adam Sieg
Jennifer Ann Gass
Indranee Rajapreyar
Publikationsdatum: 22.03.2016
Verlag: Springer US
Erschienen in: Heart Failure Reviews / Ausgabe 4/2016
Print ISSN: 1382-4147
Elektronische ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-016-9546-7

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2016

Tissue thyroid hormones and thyronamines

Thyroid hormones and heart failure

Long-term efficacy of implantable cardiac resynchronization therapy plus defibrillator for primary prevention of sudden cardiac death in patients with mild heart failure: an updated meta-analysis

Thyroid hormones and cardiac remodeling

Thyroid hormones and the heart